Overview of New Targets for Hepatitis B Virus: Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond.
| Autor: | Lok J; Institute of Liver Studies, King's College Hospital, London, SE5 9RS, UK., Guerra Veloz MF; Institute of Liver Studies, King's College Hospital, London, SE5 9RS, UK., Agarwal K; Institute of Liver Studies, King's College Hospital, London, SE5 9RS, UK. Electronic address: kosh.agarwal@kcl.ac.uk. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinics in liver disease [Clin Liver Dis] 2023 Nov; Vol. 27 (4), pp. 857-876. Date of Electronic Publication: 2023 Jul 11. |
| DOI: | 10.1016/j.cld.2023.05.003 |
| Abstrakt: | Nucleos(t)ide analogs are the cornerstone of treatment against hepatitis B virus; however, they have no direct effect on its transcriptional template (ie, covalently closed circular DNA) and so functional cure is rarely achieved. Over recent years, there has been a significant improvement in our understanding of the viral life cycle and its mechanisms of immune evasion. In this review article, we will explore novel therapeutic targets, discuss the latest data from clinical trials, and highlight future research priorities. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|